A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
Latest Information Update: 02 Aug 2023
At a glance
- Drugs AdCLD-CoV19 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Cellid Company
- 27 Jul 2023 Status changed from active, no longer recruiting to completed.
- 06 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 May 2023.
- 10 Aug 2022 Planned End Date changed from 1 Apr 2022 to 1 Dec 2022.